Takeshi Ishizaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takeshi Ishizaki has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Almaz Abdulkhaevich Aldashev
Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan
3 shared publications - Shiro Mizuno
Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan
3 shared publications - Yukihiro Umeda
University of Fukui
3 shared publications - Isamu Miyamori
Third Department of Internal Medicine, University of Fukui, 23-3 Eiheiji-cho, Matsuoka, Yoshida-gun, Fukui, Japan
2 shared publications - Maiko Kadowaki
Third Department of Internal Medicine, University of Fukui, 23-3 Eiheiji-cho, Matsuoka, Yoshida-gun, Fukui, Japan
2 shared publications Shigeru Matsukawa
Life Science Research Laboratory, University of Fukui, Fukui 910-1193, Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-5
Blunted Activation of Rho-Kinase in Yak Pulmonary Circulation
Yaks have adapted to high altitude and they do not develop hypoxic pulmonary hypertension. Although we previously identified the important role of augmented nitric oxide synthase activity in the yak pulmonary circulatory system, evidence of the direct involvement of Rho-kinase as a basal vascular tone regulator is lacking. Four domesticated male pure-bred yaks and four bulls that were born and raised at an altitude of 3000 m in the Tien-Shan mountains were studied at an altitude of 3,100 m. Mean pulmonary artery pressure (mPAP) was measured before and after fasudil (60 mg in 20 mL of saline) was intravenously administered using a Swan-Ganz catheter at a rate of 3.3 mL/min for 30 min. Fasudil decreased mPAP in bulls fromto mmHg () after 15 min and the level was maintained for 30 min, but it merely blunted mPAP in yaks fromtoand mmHg after 5 and 30 min, respectively. These findings comprise the first evidence of a modest role of Rho-kinase in the maintenance of pulmonary artery pressure in the yak.- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-5
Open AccessBlunted Activation of Rho-Kinase in Yak Pulmonary Circulation
Yaks have adapted to high altitude and they do not develop hypoxic pulmonary hypertension. Although we previously identified the important role of augmented nitric oxide synthase activity in the yak pulmonary circulatory system, evidence of the direct involvement of Rho-kinase as a basal vascular tone regulator is lacking. Four domesticated male pure-bred yaks and four bulls that were born and raised at an altitude of 3000 m in the Tien-Shan mountains were studied at an altitude of 3,100 m. Mean pulmonary artery pressure (mPAP) was measured before and after fasudil (60 mg in 20 mL of saline) was intravenously administered using a Swan-Ganz catheter at a rate of 3.3 mL/min for 30 min. Fasudil decreased mPAP in bulls fromto mmHg () after 15 min and the level was maintained for 30 min, but it merely blunted mPAP in yaks fromtoand mmHg after 5 and 30 min, respectively. These findings comprise the first evidence of a modest role of Rho-kinase in the maintenance of pulmonary artery pressure in the yak. - 1 September 2012
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 13 (3) , 217-223
Bosentan Reduces Pulmonary Artery Pressure in High Altitude Residents
Kojonazarov, Baktybek, Jainagul Isakova, Baktybek Imanov, Nurmira Sovkhozova, Talantbek Sooronbaev, Takeshi Ishizaki, and Almaz A. Aldashev. Bosentan reduces pulmonary artery pressure in high altitude residents. High Alt Med Biol. 13:217–223, 2012.—Endothelin-1 (ET-1) plays a critical role in the regulation of pulmonary vascular tone. The aim of this study was to investigate the role of ET-1 in the pathogenesis of high altitude pulmonary arterial hypertension (HAPH). Methods: Pulmonary artery pressure (PAP) was measured by echocardiography in permanent residents of the Kyrgyz Republic (3200–4000 m above sea level) both before and 3 h after a single oral dose of ET receptor antagonist, bosentan (125 mg). Plasma ET-1 levels were measured by ELISA assay. Genomic DNA was extracted from peripheral blood samples and the frequency of -3a and -4a alleles of the ET-1 gene determined by PCR. Results: Plasma ET-1 in HAPH highlanders was significantly higher than in healthy subjects (7.05±2.35 vs. 4.65±1.65 pg/ml, pppvs. 0.3, χ2=4.3, p=0.03). Conclusion: Increased ET-1 levels play an important role in development of HAPH.
- 1 September 2012
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 13 (3) , 217-223
Bosentan Reduces Pulmonary Artery Pressure in High Altitude Residents
Kojonazarov, Baktybek, Jainagul Isakova, Baktybek Imanov, Nurmira Sovkhozova, Talantbek Sooronbaev, Takeshi Ishizaki, and Almaz A. Aldashev. Bosentan reduces pulmonary artery pressure in high altitude residents. High Alt Med Biol. 13:217–223, 2012.—Endothelin-1 (ET-1) plays a critical role in the regulation of pulmonary vascular tone. The aim of this study was to investigate the role of ET-1 in the pathogenesis of high altitude pulmonary arterial hypertension (HAPH). Methods: Pulmonary artery pressure (PAP) was measured by echocardiography in permanent residents of the Kyrgyz Republic (3200–4000 m above sea level) both before and 3 h after a single oral dose of ET receptor antagonist, bosentan (125 mg). Plasma ET-1 levels were measured by ELISA assay. Genomic DNA was extracted from peripheral blood samples and the frequency of -3a and -4a alleles of the ET-1 gene determined by PCR. Results: Plasma ET-1 in HAPH highlanders was significantly higher than in healthy subjects (7.05±2.35 vs. 4.65±1.65 pg/ml, pppvs. 0.3, χ2=4.3, p=0.03). Conclusion: Increased ET-1 levels play an important role in development of HAPH.
- Open Access
- 31 January 2012
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 39 (2) , 496-498
Effects of fasudil in patients with high-altitude pulmonary hypertension: Table 1–
- 31 January 2012
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 39 (2) , 496-498
Open AccessEffects of fasudil in patients with high-altitude pulmonary hypertension: Table 1–
- 1 December 2011
- Published by Elsevier in Respiratory Medicine
- Vol. 105 (12) , 1931-1938
Small airway disease associated with Sjögren’s syndrome: Clinico-pathological correlations
- 1 December 2011
- Published by Elsevier in Respiratory Medicine
- Vol. 105 (12) , 1931-1938
Small airway disease associated with Sjögren’s syndrome: Clinico-pathological correlations
- Open Access
- 6 March 2009
- Published by Springer Nature in Respiratory Research
- Vol. 10 (1) , 17
Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways
Hypoxia induces the proliferation of lung fibroblasts in vivo and in vitro. However, the subcellular interactions between hypoxia and expression of tumor suppressor p53 and cyclin-dependent kinase inhibitors p21 and p27 remain unclear.
- 6 March 2009
- Published by Springer Nature in Respiratory Research
- Vol. 10 (1) , 17
Open AccessHypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways
Hypoxia induces the proliferation of lung fibroblasts in vivo and in vitro. However, the subcellular interactions between hypoxia and expression of tumor suppressor p53 and cyclin-dependent kinase inhibitors p21 and p27 remain unclear.
- Open Access
- 1 November 2007
- Published by Springer Nature in Respiratory Research
- Vol. 8 (1) , 77
Effect of hypoxia and Beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: the role of p27kip1
Hypoxia induces the proliferation of pulmonary arterial smooth muscle cell (PASMC) in vivo and in vitro, and prostacyclin analogues are thought to inhibit the growth of PASMC. Previous studies suggest that p27kip1, a kind of cyclin-dependent kinase inhibitor, play an important role in the smooth muscle cell proliferation. However, the mechanism of hypoxia and the subcellular interactions between p27kip1 and prostacyclin analogues in human pulmonary arterial smooth muscle cell (HPASMC) are not fully understood.
- 1 November 2007
- Published by Springer Nature in Respiratory Research
- Vol. 8 (1) , 77
Open AccessEffect of hypoxia and Beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: the role of p27kip1
Hypoxia induces the proliferation of pulmonary arterial smooth muscle cell (PASMC) in vivo and in vitro, and prostacyclin analogues are thought to inhibit the growth of PASMC. Previous studies suggest that p27kip1, a kind of cyclin-dependent kinase inhibitor, play an important role in the smooth muscle cell proliferation. However, the mechanism of hypoxia and the subcellular interactions between p27kip1 and prostacyclin analogues in human pulmonary arterial smooth muscle cell (HPASMC) are not fully understood.
- Open Access
- 1 January 2007
- Published by Architectural Institute of Japan in Journal of Structural and Construction Engineering (Transactions of AIJ)
- Vol. 72 (616) , 33-39
RISK ESTIMATE AND PROPOSAL OF MITIGATION METHOD ON EFFLORESCENCE CAUSED ON HISTORICAL BRICK MASONRY BUILDINGS REINFORCED WITH CONCRETE
To design the mitigation method for efflorescence of historical brick masonry buildings reinforced with concrete, the flowchart for mitigating efflorescence was proposed and the efflorescence risk of actual brick masonry building was estimated by using proposed flowchart. Concretely, features on the wall, environmental conditions were grasped, and numerical simulation of water movement was performed. As a result, heavy efflorescence was observed on the part considered efflorescence risk would be high. In addition, mitigation method of efflorescence was proposed and the effect was verified by accelerated test using model wall specimen. It was considered that efflorescence could be mitigated by constructing reliable insulation layer of moisture between brick masonry wall and reinforced concrete.
- 1 January 2007
- Published by Architectural Institute of Japan in Journal of Structural and Construction Engineering (Transactions of AIJ)
- Vol. 72 (616) , 33-39
Open AccessRISK ESTIMATE AND PROPOSAL OF MITIGATION METHOD ON EFFLORESCENCE CAUSED ON HISTORICAL BRICK MASONRY BUILDINGS REINFORCED WITH CONCRETE
To design the mitigation method for efflorescence of historical brick masonry buildings reinforced with concrete, the flowchart for mitigating efflorescence was proposed and the efflorescence risk of actual brick masonry building was estimated by using proposed flowchart. Concretely, features on the wall, environmental conditions were grasped, and numerical simulation of water movement was performed. As a result, heavy efflorescence was observed on the part considered efflorescence risk would be high. In addition, mitigation method of efflorescence was proposed and the effect was verified by accelerated test using model wall specimen. It was considered that efflorescence could be mitigated by constructing reliable insulation layer of moisture between brick masonry wall and reinforced concrete.
- 1 January 2002
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 15 (1) , 25-33
Leukotoxin-activated Human Pulmonary Artery Endothelial Cell Produces Nitric Oxide and Superoxide Anion
- 1 January 2002
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 15 (1) , 25-33
Leukotoxin-activated Human Pulmonary Artery Endothelial Cell Produces Nitric Oxide and Superoxide Anion
- 1 September 1995
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 269 (3) , L326-L331
Leukotoxin, 9,10-epoxy-12-octadecenoate inhibits mitochondrial respiration of isolated perfused rat lung
To investigate how mitochondrial function was affected in leukotoxin (Lx)-,9,10-epoxy-12-octadecenoate-induced lung injury, lung mitochondria were extracted from isolated perfused rat lung with or without Lx-induced edematous injury. In the lung treated with 30 mumol of Lx, the mitochondrial respiration rate in states 3 and 4 significantly decreased (without mitochondrial uncoupling) concomitantly with increased release of lactate dehydrogenase (LDH), a parameter for cellular damage, into the perfusate and decreased ATP content in the lung tissue compared with those of untreated lung. Moreover, 30 mumol of Lx resulted in significant inhibition of cytochrome-c oxidase activity (vs. vehicle control). In contrast, lower doses of Lx (10 mumol) caused lung edema and cellular damage without evidence for mitochondrial dysfunction. We also examined cellular and mitochondrial damage in hydrostatic lung edema. Such edema showed neither suppressed mitochondrial respiration nor elevated LDH activity in perfusate, although lung wet weight increased as much as it did after 30 mumol Lx treatment. Our results suggest that the ex vivo mitochondrial dysfunction is one of the secondary (vs. initial augmented permeability) but specific manifestations of toxicity of Lx, and together with the previous reports, the ex vivo damaging effect of Lx against mitochondria may be ascribed not to its direct action on mitochondria but to Lx-derived cellular mechanism(s).
- 1 September 1995
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 269 (3) , L326-L331
Leukotoxin, 9,10-epoxy-12-octadecenoate inhibits mitochondrial respiration of isolated perfused rat lung
To investigate how mitochondrial function was affected in leukotoxin (Lx)-,9,10-epoxy-12-octadecenoate-induced lung injury, lung mitochondria were extracted from isolated perfused rat lung with or without Lx-induced edematous injury. In the lung treated with 30 mumol of Lx, the mitochondrial respiration rate in states 3 and 4 significantly decreased (without mitochondrial uncoupling) concomitantly with increased release of lactate dehydrogenase (LDH), a parameter for cellular damage, into the perfusate and decreased ATP content in the lung tissue compared with those of untreated lung. Moreover, 30 mumol of Lx resulted in significant inhibition of cytochrome-c oxidase activity (vs. vehicle control). In contrast, lower doses of Lx (10 mumol) caused lung edema and cellular damage without evidence for mitochondrial dysfunction. We also examined cellular and mitochondrial damage in hydrostatic lung edema. Such edema showed neither suppressed mitochondrial respiration nor elevated LDH activity in perfusate, although lung wet weight increased as much as it did after 30 mumol Lx treatment. Our results suggest that the ex vivo mitochondrial dysfunction is one of the secondary (vs. initial augmented permeability) but specific manifestations of toxicity of Lx, and together with the previous reports, the ex vivo damaging effect of Lx against mitochondria may be ascribed not to its direct action on mitochondria but to Lx-derived cellular mechanism(s).